Company intelligence / Profile preview
Ladon Therapeutics
Szeged, Csongrád-Csanád, Hungaryladon.life ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
Ladon Therapeutics is developing first-in-class artificial amino acid-based small molecules using its proprietary A3SMO® platform. Their lead candidate, LDN‑071, has shown efficacy in preclinical colitis models. The company aims to address major unmet needs in autoimmune and genetic diseases by overcoming limitations of both traditional small molecules and biologics with improved stability, oral bioavailability, tissue penetration, and reduced immunogenicity. No published human clinical results as of the latest available information.
- Therapeutic areas
- GastroenterologyRare DiseasesImmunology
- Modalities
- Artificial amino acid-based small molecules (A3SMO®)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
CalciMedica collaboration for pre-clinical drug testing and diagnostics platform use
Beyond the preview
Go deeper on Ladon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ladon Therapeutics.